The Impact of Residual Tumor Morphology on Prognosis, Recurrence, and Fistula Formation after Lung Cancer Resection  by Kawaguchi, Takeshi et al.
ORIGINAL ARTICLE
The Impact of Residual Tumor Morphology on Prognosis,
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Resection
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Introduction: The prognosis and proper management of patients
with microscopic residual tumor at the bronchial resection margins
(bronchial R1) remain unclear.
Methods:We performed a retrospective analysis of 74 patients who
underwent pulmonary resection for lung cancer between 1976 and
2003 and had bronchial R1. The prognosis, pattern of the recurrence,
and occurrence of the bronchopleural fistula (BPF) were analyzed
according to the types of bronchial R1 morphology: direct extension
(DIR, n  11), peribronchial extension (PER, n  54), and carci-
noma in situ (CIS, n  9).
Results: Five-year survival rates of patients with DIR, PER, and
CIS were 0, 10, and 63%, respectively. The patients with CIS
showed significantly better prognosis than those with DIR and PER
(p  0.0006, p  0.0009, respectively). No prognostic difference
was observed between patients with DIR and PER (p  0.1753).
Recurrent disease developed in 43 patients (58%). Only one of nine
patients with CIS (11%) had recurrence, whereas 6 of 11 patients
with DIR (55%) and 36 of 54 patients with PER (67%) had disease
relapse. The recurrence rate in the CIS group was significantly lower
than those of the other two groups (CIS versus DIR, p  0.036; CIS
versus PER, p  0.006, respectively). BPF formation was not
detected in patients with CIS; however, BPF developed in 3 of 11
patients with DIR (27%) and 3 of 54 patients with PER (5.6%).
Conclusions: Residual tumor morphology influenced the prognosis
of patients with postresection bronchial R1 disease.
Key Words: Non-small cell lung cancer, Lung resection, Bronchial
R1, Bronchopleural fistula.
(J Thorac Oncol. 2008;3: 599–603)
Surgical resection is the only potentially curative treatmentfor non-small cell lung cancer. A gross incomplete resec-
tion is associated with poor prognosis and high local recur-
rence and surgical complication rates.1–3 Nevertheless, sev-
eral reports have suggested that microscopic residual disease
at the bronchial margin (bronchial R1, according to the
tumor, node, metastasis classification of the International
Union Against Cancer4) does not have the adverse effect on
survival that gross residual disease does.5–12 The prognosis
and optimal postoperative management for patients with
bronchial R1 disease remain unclear.
To clarify the prognosis, pattern of recurrence, and rate
of bronchopleural fistula (BPF) formation in patients with R1
disease, we retrospectively reviewed the records of lung
cancer patients who had been treated with pulmonary resec-
tion at our hospital, focusing on the relationship between R1
morphology and outcomes.
PATIENTS AND METHODS
Patients
Between June 1976 and June 2003, 4493 patients un-
derwent pulmonary resection for primary lung cancer at the
National Cancer Center Hospital, Tokyo. We included all
patients (n 74; 1.6%) who received at least lobectomy with
mediastinal lymph node dissection and had microscopic re-
sidual tumor at the resected end of the bronchus in our
retrospective analysis. Histologic typing and disease stage
were classified according to World Health Organization clas-
sification13 and tumor, node, metastasis classification of the
International Union Against Cancer,4 respectively. We excluded
patients with small cell lung cancer or low-grade malignant
histologic types, such as carcinoid or adenoidcystic carcinoma,
from this study. Patient characteristics are shown in Table 1.
Patients included in this study tended to have advanced (stages
III and IV) disease and squamous cell histology.
Intraoperative frozen section examination of the bron-
chial margins was performed for 28 patients (38%). Although
26 of 28 patients had positive margins detected during sur-
gery they did not undergo further resection because of limited
pulmonary reserves or poor risk. Intraoperative examination
found the bronchial margins to be tumor-free for two patients,
however, postoperative analysis revealed bronchial R1 dis-
ease. Forty-six patients did not undergo intraoperative micro-
scopic analysis of the bronchial stump because the bronchial
resection line was considered tumor-free according to mac-
roscopic examination.
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Morphology of R1 Disease
Patients with bronchial R1 were classified into the
following three categories according to the residual tumor
pattern: (1) Direct extension (DIR, n  11, Figure 1A),
characterized by direct invasive extension of the main tumor
proximally in the bronchial wall; (2) Peribronchial extension
(PER, n  54, Figure 1B), which included tumor infiltration
into the peribronchial connective tissues, lymphatic perme-
ation by peribronchial lymphatic vessels, or extracapsular
infiltration of the metastatic lymph nodes; (3) Carcinoma in
situ (CIS, n  9, Figure 1C), characterized by in situ exten-
sion of the main tumor, which continued up to the bronchial
resection margin. All patients with CIS lesion had squamous
cell carcinoma.
Postoperative Therapy
Postoperative radiotherapy was administered for 21
patients (5 with DIR, 11 with PER, and 5 with CIS). Patients
in poor physical condition or with advanced disease did not
receive radiotherapy. The total radiation dose ranged from 29
to 60 Gy (median, 50 Gy). None of the patients in this study
received postoperative chemotherapy.
TABLE 1. Characteristics of Patients with Bronchial R1
Disease
Characteristics No. (%)
Sex
Male 58 (78)
Female 16 (22)
Age
Range (yr) 39–83
Median (yr) 66
Pathological stage
0 1 (1)
I 6 (8)
II 10 (14)
III 52 (70)
IV 5 (7)
Histology
Adenocarcinoma 35 (47)
Squamous cell carcinoma 34 (46)
Large cell carcinoma 3 (5)
Adenosquamous cell carcinoma 1 (1)
Giant cell carcinoma 1 (1)
Pulmonary resection
Pneumonectomy 17 (23)
With carinal resection 1
Bilobectomy 16 (22)
With bronchial resection 3
Lobectomy 41 (55)
With bronchial resection 15
Type of bronchial R1
Direct extension 11 (15)
Peribronchial extension 54 (73)
Carcinoma in situ 9 (12)
Postoperative RT
Yes 21 (28)
No 53 (72)
FIGURE 1. Schemas of bronchial R1 (A) direct extension,
(B) peribronchial extension, and (C) carcinoma in situ.
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Prognosis
Tumor recurrence was described as local or distant.
Local recurrence was defined as any recurrent disease within
the ipsilateral hemithorax or mediastinum. Recurrence was
diagnosed by bronchoscopic biopsy or noninvasive diagnos-
tic procedures such as radiography, computerized tomogra-
phy, magnetic resonance imaging, or bone scan.
Statistical Analysis
Survival curves were estimated by the product limit
method of Kaplan and Meier, and the differences in survival
were tested with log-rank analysis. The length of survival was
defined as the interval between the day of initial operation
and the day of death or last follow-up. Observation was
censored at the last follow-up when patients were alive, and
all deaths, including operative deaths, were considered
events. The median follow-up period for the 12 surviving
patients was 51 months. The 2 test was performed to
evaluate the correlation between bronchial R1 morphology
and recurrence. Statistical significance was set at p  0.05.
RESULTS
The median survival time for all patients with bronchial
R1 was 14 months, with actual survival rates of 57, 26, and
14% at 1, 3, and 5 years, respectively (Figure 2). According
to the bronchial R1 morphology, the 5-year survival rates of
patients with DIR, PER, and CIS were 0, 10, and 63%,
respectively (Figure 3). Patients with CIS fared significantly
better than did patients with the other types of bronchial R1
(DIR versus CIS, p  0.0006; PER versus CIS, p  0.0009).
On the other hand, we detected no difference in the prognoses
of patients with DIR and PER (p  0.1753). Among patients
with DIR and PER, histologic classification or pathologic
nodal status did not affect the probability of survival (squa-
mous cell carcinoma versus nonsquamous cell carcinoma,
p  0.4227; pN0–1 versus pN2, p  0.1768).
During follow-up, progressive disease developed in 43
(58%), 20 patients were free of disease, and details of
predeath status were not known for 11 patients. Correlations
between the first site of relapse and bronchial R1 morphology
are shown in Table 2. In patients with CIS, local recurrence
developed in only one patient (11%) and no distant metastasis
was observed. On the other hand, recurrence rates of patients
with DIR (54%) and PER (66%) were significantly higher
than that of patients with CIS (p  0.036, p  0.006,
respectively), and 34 of the 42 recurrences (81%) included
distant metastases. Among 21 patients treated with postoper-
ative radiotherapy, 12 patients relapsed (Table 3). Despite the
radiotherapy, local recurrence developed in 4 patients (19%).
Furthermore, in DIR and PER group, half of the patients that
received radiotherapy (8 of 16) had recurrences at the distant
sites. Prognosis was not affected by postoperative radiother-
apy (p  0.667, Figure 4).
TABLE 2. First Site of Relapse in Patients with Bronchial R1
DIR
(n  11) (%)
PER
(n  54) (%)
CIS
(n  9) (%)
Local 2 (18) 6 (11) 1 (11)
Distant 4 (36) 26 (48) 0 (0)
Local  distant 0 (0) 4 (7) 0 (0)
Total 6 (54) 36 (66) 1 (11)
DIR, direct extension; PER, peribronchial extension; CIS, carcinoma in situ.
TABLE 3. First Site of Relapse in 21 Patients Undergoing
Postoperative Radiotherapy
DIR
(n  5) (%)
PER
(n  11) (%)
CIS
(n  5) (%)
Local 1 (20) 2 (18) 1 (20)
Distant 2 (40) 5 (45) 0 (0)
Local  distant 0 (0) 1 (9) 0 (0)
Total 3 (60) 8 (72) 1 (20)
DIR, direct extension; PER, peribronchial extension; CIS, carcinoma in situ.FIGURE 2. Cumulative survival for the entire group.
FIGURE 3. Survival by type of bronchial R1 disease. Carci-
noma in situ (CIS) versus direct extension (DIR), p  0.0006;
CIS versus peribronchial extension (PER), p  0.0009, DIR
versus PER, p  0.18.
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BPF developed in six patients (8.1%), 3 of the 11
patients with DIR (27%) and 3 of the 54 patients with PER
(5.6%). BPF formation was not detected in patients with CIS.
One of the six patients with BPF was treated with postoper-
ative radiotherapy. The mortality rate of patients with BPF
was 50% (3 of 6).
DISCUSSION
Gross residual tumors at the resection margin adversely
affect the outcome of patients with non-small cell lung
cancer; patients with microscopic residual disease at a bron-
chial resection margin tend to survive longer than do patients
with residual gross disease.3 The incidence of bronchial R1
resection in this study (1.6%) was slightly lower than that
reported in the literature (2.6–5.4%).5,7–11 In our clinical
practice, we find that the incidence of cancer arising in the
periphery of lung is increasing, therefore the incidence of
bronchial R1 disease is less than that reported for this study.
The reported three-year survival rate of patients with
bronchial R1 varies from 24 to 40%,7,10 and the 3-year
survival rate detected in this series fell within this range
(26%). Because of the heterogeneity of bronchial R1 disease,
many authors classify the pattern of bronchial R1 and eval-
uate prognoses according to these patterns.5–8,10–12 Soorae
and Stevenson12 analyzed the morphology of microscopic
residual tumor at the resected end of bronchus, and classified
bronchial R1 disease into four patterns: direct extension of
the main tumor mass proximally in the bronchial wall; lym-
phatic permeation through peribronchial and submucosal
lymphatic vessels; extension through parabronchial tissue;
and in situ extension. In their study, 15 of 64 patients with
bronchial R1 disease survived for more than 5 years. The
long-term survivors consisted of seven patients with in situ
extension, 7 with DIR, and one with in parabronchial
extension. There were no long-term survivors among pa-
tients with lymphatic permeation. Therefore, they con-
cluded that bronchial R1 morphology was associated with
outcome. Several other studies, including ours, have used
the same classification scheme when analyzing patients
with bronchial R1.5–8,10,11
Among the different morphologies of R1 disease, CIS
has been reported to be a favorable indicator of prognosis.6,8
Snijder et al.8 analyzed the outcomes of patients with resected
stage I disease with bronchial R1 and found no difference in
survival between patients with residual CIS and the same-
stage R0 patients. Massard et al.6 reported that cancer-related
death was observed in only 5 of 20 patients with CIS (distant
metastases in three, combined local recurrence and distant
metastases in one, and second primary lung cancer in one). In
previous studies, the cause of good prognosis of patients with
residual CIS disease was speculated to be: (1) spontaneous
regression of residual neoplastic cells caused by smoking
cessation; (2) interference with nutrition; (3) local scarring
phenomena; or (4) unknown immunologic pathways.8,12 In
our study, the 5-year survival rate of patients with CIS was
significantly higher than that of patients with the other two
morphologic subtypes (DIR and PER). Cancer-related death
occurred in only one of nine patients with CIS. In addition,
four of eight patients without recurrence had no postoperative
radiotherapy. According to these observations, the prognostic
impact of residual CIS disease was different from that of the
other types of R1 disease. The role of postoperative radio-
therapy for residual CIS disease needs to be further refined.
Some patients with CIS disease might be followed up with
observation only. Otherwise, the indication for radiother-
apy should be determined according to the amount of
residual tumor.
We found no difference in the prognoses of patients
with either DIR or PER. Among patients with such morpho-
logic subtypes, neither tumor histology nor stage was asso-
ciated with prognosis. Previous studies have reported prog-
nostic differences related to the pattern of bronchial R1,
disease stage, or histology.5,7,9,10 Liewald et al.10 reported that
the prognosis for patients with extramucosal microscopic
residual disease (infiltrating by peribronchial lymphatics or con-
nective tissue) was worse than that for patients with mucosal
microscopic residual disease (spreading directly along endo-
bronchial pathway). Others have found prognostic differences
associated with disease stage, histology, or presence of lym-
phangiosis carcinomatosa at the bronchial resection margin.5,7,9
Nevertheless, according to our analysis, the presence of bron-
chial R1 disease, except for CIS, was latently associated with
disease advancement regardless of tumor histology and stage.
There is no established standard of care for bronchial
R1 disease. Several authors have noted that local recurrence
develops more often in patients with bronchial R1 than in
patients without residual tumor.6–11 Some of these studies
recommended repeated resection for selected cases to prevent
local recurrence.7,8,10,11 Nevertheless, 34 of 42 relapsed pa-
tients in our study (81%) with DIR or PER disease had distant
metastases, and local therapy such as postoperative radiation
did not affect the survival. Therefore, postoperative local
therapy might not improve overall survival, since the local
therapy does not control distant metastases. The benefit of
postoperative local therapy for patients with DIR or PER
disease should be considered limited.
FIGURE 4. Survival in patients with or without postopera-
tive radiotherapy (RT). RT versus non-RT, p  0.667.
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In this series, the 8.1% incidence of BPF in patients with
R1 disease exceeded that of patients without residual tumor at
our hospital (1.5%).14 Previous studies have reported that the
high incidence of BPF was the cause of high mortality rate of
patients with bronchial R1 disease.7,12 Some have speculated
that the occurrence of BPF might be related to the presence of
residual tumor in the bronchial mucosa.7,11,12 Based on this
study, in which there was no BPF in patients with CIS, in situ
extension of tumor cells at the bronchial stump might not be
responsible for fistula formation. On the other hand, full thick-
ness invasion to the bronchial partition, which is seen in DIR or
PER pattern disease, might promote BPF formation.
We conclude that residual tumor morphology influ-
ences the prognosis of patients with bronchial R1 disease
after lung cancer resection. The outcomes of patients with
CIS are different from those of patients with DIR and PER.
The morphology of the residual disease at the resected margin
should play an important role in planning postoperative
management for patients with bronchial R1.
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